Long-term human survival cohorts and Phase 3 prevention trials covering UKPDS 34 / TAME Metformin AMPK longevity pathways, muscle protein synthesis across eight decades of life, and adult vaccine coadministration trials. Explore 817 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
SDT-001 demonstrated superior efficacy at week 6 in ADHD-RS-IV compared to.
Our findings suggest that gut microbiome communities modulate clinical outcomes in PCNSL patients undergoing standard treatment.
Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM.
In this low to moderate risk population with type 2 diabetes, liraglutide did not change vascular inflammation assessed as [ 18 F]-fluorodeoxyglucose uptake compared with placebo.
In the KATHERINE study, T-DM1 demonstrated increased efficacy compared to trastuzumab in Chinese patients.
PLEX improves short-term survival and disease severity in A-ACLF and may be a valuable therapeutic option where transplantation is limited.
Treatment with ezetimibe/simvastatin versus rosuvastatin resulted in a similar improvement of carotid atherosclerotic plaque inflammation, suggesting their equivalent anti-inflammatory effects.
Decreased local inflammatory response and plaque stabilization on IB imaging were observed after 6 months of telmisartan treatment.
PET/CT has reasonable NPV but poor PPV.
Treatment with liraglutide for 52 weeks improved glucose tolerance, FPG, HbA1c and bodyweight in women with overweight/obesity and pGDM.
We found little evidence to support the benefits of an aerobic exercise intervention on neurocognitive performance in patients with MDD.
Based on the results of this analysis, Isa-Kd is a novel treatment option for East Asian patients with relapsed MM.
Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran.
Among 118 children screened for eligibility, 100 were randomly assigned to receive zinc supplementation (n = 50) or placebo (n = 50) (mean [SD] age, 36.0 [13.2] months; 45 female [45%]).
Urinary miR-191 and miR-200a showed potential for discriminating patients with UTUC from healthy controls and may complement urine cytology, particularly in patients with negative/suspicious cytology.
The results of this subgroup analysis of PUNCH CD3-OLS suggest RBL is safe and efficacious in patients with IBD.
Sensitivity index underlines the quality target product profile of TCS10 in the runway of emergency casualty care.
The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvastatin in patients with T2DM and concomitant high cholesterol.
A total of 43 patients (mean [SD] age, 75.0 [5.7] years, 41 male [95.3%]) underwent baseline CMR imaging (21 [48.8%] received vutrisiran; 22 [51.2%] received placebo).
IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma.
TRT by CT is compatible with TRT by IMIM.
OSA is a significant risk factor for all-cause mortality and cardiac mortality.
There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay.
During statin therapy, serum hs-cTnI levels decreased rapidly within weeks of treatment, suggesting an effect beyond long-term atherosclerosis regression.
The entire study population experienced long-term survival, with median OS well over five years.
A total of 68 HCWs met the eligibility criteria were randomly allocated to receive HCQ (n = 36) or not (n = 32).
Functional liver or kidney damages were not observed for all patients.
Repeated inhalations with EXO-CD24 is associated with improved survival and HRQoL up to 4.6 years post-treatment.
Flaxseed supplementation may benefit women with PCOS by increasing FSH levels and decreasing the LH/FSH ratio, suggesting its potential as a complementary intervention for managing hormonal disturbances in PCOS.
Placebo had little impact on convulsive seizure-free days and Caregiver Global Impression of Change versus baseline, suggesting that these metrics may help differentiate placebo and active treatment effects in future studies.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
